Strong Revenue and EBITDA Growth
Third quarter total revenue was $2.9 billion, representing 29% growth year-over-year. Adjusted EBITDA was $151 million, representing 16% growth year-over-year.
Pharmacy Solutions Segment Performance
Pharmacy Solutions revenue of $2.3 billion represented 35% growth compared with the third quarter of last year. Infusion and Specialty business grew 42% year-over-year, while home community pharmacy revenue grew 19% year-over-year.
Provider Services Segment Growth
Provider Services revenue grew 10% year-over-year with home healthcare revenue growing 13% and community and rehab care revenue growing 8% year-over-year.
Guidance Increase
The company raised the midpoint of its total revenue and adjusted EBITDA guidance for 2024, with total revenue now expected to be in the range of $11.0 billion to $11.3 billion and adjusted EBITDA in the range of $580 million to $585 million.